In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 109 for your search:

At Hospital/Institution:  Massey Cancer Center at Virginia Commonwealth University
Trial Type:  All
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 609, U01HL069294, BMT CTN 0801, U01HL069294-06, NCT01106833

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02616, ACNS0822, CDR0000688443, U10CA098543, COG-ACNS0822, NCT01236560

Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000732604, COG-ANHL1131, ANHL1131, NCT01595048

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: ANBL12P1, COG-ANBL12P1, NCI-2012-02211, U10CA098543, NCT01798004

Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2009-01064, ANBL0032, U10CA098543, U10CA030969, COG-ANBL0032, COG-P9842, NCT00026312

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 3 to 21 at diagnosis
Sponsor: NCI, Other
Protocol IDs: ACNS0331, COG-ACNS0331, CDR0000365506, NCT00085735

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00509, E1505, U10CA021115, ECOG-E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 3
Sponsor: NCI, Other
Protocol IDs: ACNS0334, NCI-2009-00338, COG-ACNS0334, CDR0000483683, U10CA098543, NCT00336024

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms Tumor

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30 at diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000487540, COG-AREN0532, AREN0532, NCT00352534

10.

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI, Other
Protocol IDs: ACNS0332, NCI-2009-00336, COG-ACNS0332, CDR0000511991, U10CA098543, R01CA114567, NCT00392327

11.

Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00587, GOG-0213, U10CA027469, NCT00565851

12.

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 10 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000573987, COG-ARET0321, ARET0321, NCT00554788

13.

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770

14.

Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000582632, EORTC-26053, CAN-NCIC-CEC1, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, MERCK-EORTC-26053, MRC-BR14, COGNO-EORTC-26053, CEC1, NCT00626990

15.

Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00469, CALGB 30607, CDR0000597649, U10CA031946, NCT00693992

16.

Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000640442, NCCTG-N0577, EORTC-26081-22086, EudraCT-2008-007295-14, N0577, NCT00887146

17.

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01952, CALGB 90601, CDR0000649174, U10CA031946, NCT00942331

18.

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Under 30 at initial diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000649716, COG-AREN0534, AREN0534, NCT00945009

19.

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000651458, GOG-0261, NCT00954174

20.

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000654697, ECOG-E3F05, E3F05, NCT00978458

21.

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, U10CA098543, NCT00980460

22.

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01981, E1208, ECOG-E1208, CDR0000657952, U10CA021115, NCT01004978

23.

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000666482, ECOG-E5508, E5508, NCT01107626

24.

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NLG0405, OBA# 0912-1013, NCT01072981

25.

Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000668388, SWOG-S0931, S0931, NCT01120249

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map